Skip to content

Upper GI Outcomes Following EMR

Outcomes of Endoscopic Resection in the Upper Gastrointestinal Tract

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02305290
Acronym
UGI-EMR
Enrollment
200
Registered
2014-12-02
Start date
2014-08-31
Completion date
2023-09-30
Last updated
2025-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma, Villous

Brief summary

The purpose of this study is to evaluate the long-term outcomes of Endoscopic Resection (ER) of superficial lesions of the Upper Gastrointestinal Tract(UGIT)

Detailed description

Endoscopic resection (ER) of superficial lesions of the upper gastrointestinal tract is a safe and effective surgery-sparing modality in experienced hands. It is often curative of dysplastic lesions and is associated with minimal complications and high patient acceptance (1-5). Westmead Hospital has accumulated a significant amount of experience in the removal of such lesions; however, there is limited research to document the long term outcomes of patients undergoing endoscopic resection.The purpose of this study is to evaluate the long-term outcomes of ER of superficial lesions of the UGIT.

Interventions

PROCEDUREEndoscopic Mucosal Resection

Sponsors

Professor Michael Bourke
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* UGIT lesion \> 10mm * Lesion limited to the mucosal and/or submucosal layer (T1 lesion) * Aged 18 years or older

Exclusion criteria

* Lesion less than 10mm * Gastric lesion involves the muscularis propria (T2 lesion) on other staging modalities such as endoscopic ultrasonography (EUS) * Aged younger than 18 years

Design outcomes

Primary

MeasureTime frameDescription
Observed procedural data14 daysNumber of Participants with Adverse Events as a Measure of Safety and Tolerability Outcomes

Secondary

MeasureTime frameDescription
Analysis of the costs of this procedure compared to previous treatments14 daysPerform cost-utility analyses comparing different treatment approaches for UGIT lesions

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026